Isatuximab
- Generic Name
- Isatuximab
- Brand Names
- Sarclisa
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1461640-62-9
- Unique Ingredient Identifier
- R30772KCU0
- Background
Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on th...
- Indication
Isatuximab is indicated in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma in adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. It is also indicated in combination carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple ...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 100
- Registration Number
- NCT05665140
- Locations
- 🇩🇪
Heloisklinikum Berlin Buch GmbH, Berlin, Germany
🇩🇪Klinikum Bielefeld - Onkologie, Hämatologie, Paliativmedizin, Bielefeld, Germany
🇩🇪Universitätsklinikum Münster, Münster, Germany
Efficacy of the antiCD38 Monoclonal Antibody Isatuximab in the Treatment of PCRA by Major ABO Mismatch After Allogeneic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 90
- Registration Number
- NCT05559827
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
- Conditions
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 480
- Registration Number
- NCT05558319
- Locations
- 🇪🇸
Hospital Principe de Asturias, Alcalá de Henares, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol (ICO BADALONA), Badalona, Spain
🇪🇸Clinica Universidad Navarra (CUN), Pamplona, Navarra, Spain
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Divaya Bhutani
- Target Recruit Count
- 39
- Registration Number
- NCT05346809
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Columbia University, New York, New York, United States
Post-Autologous Transplant Maintenance with Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT05344833
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 108
- Registration Number
- NCT05298683
- Locations
- 🇬🇷
General Hospital of Athens "Evangelismos", Athens, Greece
🇬🇷Anticancer Oncology Hospital of Athens "Agios Savvas", Athens, Greece
🇬🇷General Hospital of Athens "Alexandra", Athens, Greece
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
- Conditions
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 75
- Registration Number
- NCT05272826
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 51
- Registration Number
- NCT05147493
- Locations
- 🇬🇷
Anticancer Oncology Hospital of Athens "Agios Savvas", Athens, Greece
🇬🇷University General Hospital of Ioannina, Ioannina, Greece
🇬🇷Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT05145400
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 317
- Registration Number
- NCT05137054
- Locations
- 🇺🇸
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.